SCHEMBL4897243

SCHEMBL4897243

CC(Nc1ccc(Cl)cc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.52
CNR1 P21554 3/20 0.52
CYP19A1 P11511 1/20 0.46
PDE2A O00408 1/20 0.45
KCNH2 Q12809 1/20 0.44
TMEM97 Q5BJF2 1/20 0.44
UTS2R Q9UKP6 3/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
MMP2 P08253 1/20 0.42
RHOC P08134 1/20 0.42
RHOA P61586 1/20 0.42
TP53 P04637 1/20 0.42
P2RX3 P56373 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7566604 0.83 GAA (0.61) KCNH3
SCHEMBL6542384 0.83 ALDH1A1 (0.57) CNR1KCNH2MEN1MAPK1HTT
SCHEMBL6542509 0.83 ALDH1A1 (0.57) CNR1KCNH2MEN1MAPK1HTT
SCHEMBL12204424 0.78 CYP19A1 (0.49) CNR2CNR1CYP19A1PDE2AKCNH2
SCHEMBL8038878 0.77 GAA (0.68) CYP19A1MAPTMEN1MAPK1HTT
SCHEMBL11205766 0.77 ALDH1A1 (0.62) MAPTMEN1MAPK1HTTKMT2A
SCHEMBL2931121 0.77 ALDH1A1 (0.62) MAPTMEN1MAPK1HTTKMT2A
SCHEMBL28676692 0.77 GAA (0.61) CNR2CNR1MAPTMEN1MAPK1
SCHEMBL10389939 0.77 ALDH1A1 (0.62) MAPTMEN1MAPK1HTTKMT2A
SCHEMBL28277730 0.76 PDE2A (0.47) CNR2CNR1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249180-A1 MALONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249180-A1 MALONAMIDES AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, MTNR1B CNR2 19/4885CNR1 9/4885CYP19A1 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.